Magnetic resonance spectroscopy and schizophrenia: what have we learnt?

References

• Frangou S, Murray RM. Imaging as a tool in exploring the neurodevelopment and genetics of schizophrenia. British Medical Bulletin 1996; 52: 587–596
   PubMed Web of Science ®Google Scholar
• Andrew ER. A historical review of NMR and its clinical applications. British Medical Bulletin 1984; 40: 115–119
   PubMed Web of Science ®Google Scholar
• Bloch F, Hansen WW, Packard ME. Nuclear induction. Physics Review 1946; 69: 127
   Google Scholar
• Purcell EM, Torry HC, Pound CV. Resonance absorption by nuclear magnetic moments in a solid. Physics Review 1946; 69: 37
   Google Scholar
• Keshavan MS, Cohen JD. Magnetic resonance spectroscopy and functional MRI. Brain imaging in psychiatry, S Lewis, N Higgins. Blackwell Science, Oxford 1996; 116–137
   Google Scholar
• Keshavan MS, Kapur SK, Pettegrew JW. Magnetic resonance spectroscopy in psychiatry: potential, pitfalls, and promise. American Journal of Psychiatry 1991; 148: 976–985
   PubMed Web of Science ®Google Scholar
• Passe TJ, Charles HC, Rajagopalan P, Krishnan KR. Nuclear magnetic resonance spectroscopy: a review of neuropsychiatric applications. Progress in Neuro‐Psychopharmacology and Biological Psychiatry 1995; 19: 541–563
   PubMed Web of Science ®Google Scholar
• Edelman RR, Warach S. Magnetic resonance imaging. New England Journal of Medicine 1993; 328: 708–715
   PubMed Web of Science ®Google Scholar
• Guze BH. Magnetic resonance spectroscopy. Archives of General Psychiatry 1991; 48: 572–574
   PubMed Web of Science ®Google Scholar
• Maier M. In vivo magnetic resonance spectroscopy. British Journal of Psychiatry 1995; 167: 299–306
   PubMed Web of Science ®Google Scholar
• Frangou S, Williams SCR. Magnetic resonance spectroscopy in psychiatry: basic principles and applications. British Medical Bulletin 1996; 52: 474–485
   PubMed Web of Science ®Google Scholar
• Kegeles LS, Humaran TJ, Mann JJ. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biological Psychiatry 1998; 44: 382–398
   PubMed Web of Science ®Google Scholar
• Maier M, Ron MA, Barker GJ, Tofts PS. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in Schizophrenia. Psychological Medicine 1995; 25: 1201–1209
   PubMed Web of Science ®Google Scholar
• Volz PH, Rzanny R, May S, et al. 31P magnetic resonance Spectroscopy in the dorsolateral prefrontal cortex of schizophrenics with a volume selective technique – preliminary findings. Biological Psychiatry 1997; 41: 644–648
   PubMed Web of Science ®Google Scholar
• Volz H‐P, Rzanny R, Rossger G, et al. 31Phosphrous magnetic resonance spectrosopy of the dorsolateral prefrontal region in schizophrenia – a study including 50 patients and 36 controls. Biological Psychiatry 1998; 44: 382–398
   PubMed Web of Science ®Google Scholar
• Deicken RF. 31P‐MRS, of the human brain in the study of schizophrenia. NMR spectroscopy in psychiatric brain disorders, HA Nasrallah, JW Pettegrew. American Psychiatric Press, Washington, DC 1995; 79–106
   Google Scholar
• Pettegrew JW, Keshavan MS, Minshew NJ. 31P. Nuclear magnetic resonance spectroscopy. Neurodevelopment and schizophrenia. Schizophrenia Bulletin 1993; 19: 35–53
   PubMed Web of Science ®Google Scholar
• Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magnetic Resonance Quarterly 1994; 10: 191–247
   PubMedGoogle Scholar
• George TP, Spence MW. Alterations of membrane phospholipid metabolism in patients with schizophrenia assessed by phosphorous magnetic resonance spectroscopy. Archives of General Psychiatry 1996; 53: 1065–1066
   PubMed Web of Science ®Google Scholar
• Williamson PC, Brauer M, Leonard S, Thompson T, Drost D. 31P magnetic resonance spectroscopy studies in schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids 1996; 55: 115–118
   PubMed Web of Science ®Google Scholar
• Otsuki S, Akiyama K. Neurochemical studies of schizophrenia in Japan. Psychiatry and Clinical Neurosciences 1997; 51: 347–356
   PubMed Web of Science ®Google Scholar
• Buckley PF, Waddington JL. Magnetic resonance spectroscopy in schizophrenia: a nascent technology for a neurodevelopmental disorder?. Biological Psychiatry 1994; 36: 789–791
   PubMed Web of Science ®Google Scholar
• Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC. Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 1991; 353: 164–167
   PubMed Web of Science ®Google Scholar
• Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?. Journal of Psychiatric Research 1982; 17: 319–334
   PubMed Web of Science ®Google Scholar
• Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 1987; 44: 660–669
   PubMed Web of Science ®Google Scholar
• Pettegrew JW, Keshavan MS, Panchalingam K, et al. Alterations in brain high‐energy phosphate and membrane phospholipid metabolism in first‐episode, drug‐naive schizophrenics. Archives of General Psychiatry 1991; 48: 563–568
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Pettegrew JW. Phosphorus 31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia. Archives of General Psychiatry 1991; 48: 1112–1113
   PubMed Web of Science ®Google Scholar
• Stanley JA, Williamson PC, Drost DJ, et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorous magnetic resonance spectroscopy. Archives of General Psychiatry 1995; 52: 399–406
   PubMed Web of Science ®Google Scholar
• Hinsberger AD, Williamson PC, Carr TJ, et al. Magnetic resonance imaging volumetric and Phosphorous 31 magnetic resonance spectroscopy measurements in schizophrenia. Journal of Psychiatry and Neuroscience 1997; 22: 111–117
   PubMed Web of Science ®Google Scholar
• Williamson P, Drost D. localised Phosphorous 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Archives of General Psychiatry 1991; 48: 578
   PubMed Web of Science ®Google Scholar
• Stanley JA, Williamson PC, Drost DJ, et al. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P‐MR spectroscopy study. Schizophrenia Research 1994; 13: 209–215
   PubMed Web of Science ®Google Scholar
• Kato T, Shiori T, Murashita J, Hamakawa H, Inubushi T, Takahashi S. Lateralised abnormality of high‐energy phosphate and bilateral reduction of phosphomonoester measured by phosphorous‐31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Research: Neuroimaging 1995; 61: 151–160
   PubMed Web of Science ®Google Scholar
• Deicken RF, Calabrese G, Merrin EL, et al. 31Phosphrous magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biological Psychiatry 1994; 36: 503–510
   PubMed Web of Science ®Google Scholar
• Potwarka J, Drost DJ, Williamson PC. A 2D 31P chemical shift imaging study with 1H decoupling of medicated schizophrenics and healthy controls [abstract]. Proceedings of the International Society of Magnetic Resonance Medicine 1997; 2: 1224
   Google Scholar
• Volz HP, Roßger G, Riehemann S, et al. Increase of phosphodiesters during neuroleptic treatment of chizophrenics: a longitudinal 31P‐magnetic resonance spectroscopic study. Biological Psychiatry 1999; 45: 1221–1225
   PubMed Web of Science ®Google Scholar
• Pantelis C, Barnes TR, Nelson HE, et al. Fronto‐striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997; 120: 1823–1843
   PubMed Web of Science ®Google Scholar
• Weinberger DR. Anteromedial temporo‐prefrontal connectivity: a functional neuroanatomical system implicated in schizophrenia. Psychopathology and the brain, BJ Carroll, JE Barrett. Raven Press, New York, NY 1991; 25–43
   Google Scholar
• Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal‐limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. American Journal of Psychiatry 1992; 149: 890–897
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Nakano T, Takano T, Hokazono Y, Asakura T, Tsuji T. Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging. Acta Psychiatrica Scandinavica 1992; 86: 455–462
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Sanders RD, Pettegrew JW, Dombrowsky SM, Panchalingham KS. Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P‐MRS and MRI studies. Schizophrenia Research 1993; 10: 241–246
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Pettegrew JW, Reynods CF, et al. Biological correlates of slow wave sleep deficits in functional psychoses: 31P‐magnetic resonance spectroscopy. Psychiatry Research 1995; 57: 91–100
   PubMed Web of Science ®Google Scholar
• Shiori T, Kato T, Inubushi T, Murashita J, Takahashi S. Correlations of phosphomonoesters measured by phosphorous‐31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Research: Neuroimaging 1994; 55: 223–235
   Web of Science ®Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962; 10: 799–812
   Web of Science ®Google Scholar
• Deicken RF, Merrin EL, Floyd TC, Weiner MW. Correlation between left frontal phospholipids and Wisconsin card sort test performance in schizophrenia. Schizophrenia Research 1995; 14: 177–181
   PubMed Web of Science ®Google Scholar
• Volz HP, Hubner G, Rzanny R, et al. High energy phosphates in the frontal lobe correlate with the Wisconsin card sort test performance in controls, not in schizophrenics: a 31‐phosphorous magnetic resonancespectroscopic and neuropsychological investigation. Schizophrenia Research 1998; 31: 37–47
   PubMed Web of Science ®Google Scholar
• Calabrese G, Deicken RF, Fein G, Merrill EL, Schoenfeld F, Weiner MW. 31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia. Biological Psychiatry 1992; 32: 26–32
   PubMed Web of Science ®Google Scholar
• Fukuzako H, Fukuzako T, Takeuchi K, et al. Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms. Progress in Neuro‐Psychopharmacology and Biological Psychiatry 1996; 20: 629–640
   PubMed Web of Science ®Google Scholar
• O'Callaghan EO, Redmond O, Ennis R, et al. Initial investigation of the left temporoparietal region in schizophrenia by 31P magnetic resonance spectroscopy. Biological Psychiatry 1991; 29: 1149–1152
   PubMed Web of Science ®Google Scholar
• Robbins TW. Cognitive deficits in schizophrenia and Parkinson's disease: neural basis and the role of dopamine. The mesolimbic dopamine system: from motivation to action, P Willner, J Scheel‐Kruger. John Wiley, Chichester, UK 1991; 497–528
   Google Scholar
• Pantelis C, Brewer WJ. Neurocognitive and neuro‐behavioural patterns and the syndromes of schizophrenia: role of frontal–subcortical networks. Schizophrenia: a neuropsychological perspective, C Pantelis, HE Nelson, TRE Barnes. John Wiley, Chichester, UK 1996; 317–343
   Google Scholar
• Pantelis C, Barnes TRE, Nelson HE. Is the concept of frontal–subcortical dementia relevant to schizophrenia?. British Journal of Psychiatry 1992; 160: 442–460
   PubMed Web of Science ®Google Scholar
• Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. Journal of Neuroscience 1993; 13: 981–989
   PubMed Web of Science ®Google Scholar
• Erecinska M, Silver IA. Metabolism and role of glutamate in mammalian brain. Progress in Neurobiology 1990; 35: 245–296
   PubMed Web of Science ®Google Scholar
• Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Investigative Radiology 1996; 31: 345–352
   PubMed Web of Science ®Google Scholar
• Deicken RF, Zhou L, Schuff N, Weiner MW. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophrenia Research 1997; 27: 65–71
   PubMed Web of Science ®Google Scholar
• Buckley PF, Moore C, Long H, et al. 1H‐Magnetic resonance spectrosopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental and cognitive correlates. Biological Psychiatry 1994; 36: 792–800
   PubMed Web of Science ®Google Scholar
• Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Archives of General Psychiatry 1998; 55: 346–352
   PubMed Web of Science ®Google Scholar
• Bertolino A, Nawroz S, Mattay VS, et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. American Journal of Psychiatry 1996; 153: 1554–1563
   PubMed Web of Science ®Google Scholar
• Brooks WM, Hodde‐Vargas J, Vargas LA, Yeo RA, Ford CC, Hendren RL. Frontal lobe of children with schizophrenia spectrum disorders: a proton magnetic resonance spectroscopic study. Biological Psychiatry 1998; 43: 263–269
   PubMed Web of Science ®Google Scholar
• Bertolino A, Callicott JH, Elman I, et al. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry 1998; 43: 641–648
   PubMed Web of Science ®Google Scholar
• Bertolino A, Kumra S, Callicott JH, et al. Common pattern of cortical pathology in childhood‐onset and adult‐onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. American Journal of Psychiatry 1998; 155: 1376–1383
   PubMed Web of Science ®Google Scholar
• Hendren RL, Hodde‐Vargas J, Yeo RA, Vargas LA, Brooks WM, Ford C. Neuropsychophysiological study of children at risk for schizophrenia: a preliminary report. Journal of the Academy of Child and Adolescent Psychiatry 1995; 34: 1284–1291
   Google Scholar
• Stanley JA, Williamson PC, Drost DJ, et al. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophrenia Bulletin 1996; 22: 597–609
   PubMed Web of Science ®Google Scholar
• Bartha R, Williamson PC, Drost DJ, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never‐treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Archives of General Psychiatry 1997; 54: 959–965
   PubMed Web of Science ®Google Scholar
• Nelson MD, Saykin AJ, Flashman LA, Riordan HJ. Hippocampal volume reducation in schizophrenia as assessed by magnetic resonance imaging: a meta‐analytic study. Archives of General Psychiatry 1998; 55: 433–440
   PubMed Web of Science ®Google Scholar
• Velakoulis D, Pantelis C, McGorry PD, et al. Smaller hippocampi in chronic schizophrenia and first‐episode schizophrenia and affective psychoses: a high resolution magnetic resonance imaging study. Archives of General Psychiatry 1999; 56: 133–141
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Skinner TE, Schmalbrock P, Robitaille PM. Proton magnetic resonance spectroscopy of the hippocampal formation in schizophrenia: a pilot study. British Journal of Psychiatry 1994; 165: 481–485
   PubMed Web of Science ®Google Scholar
• Maier M, Ron MA. Hippocampal age‐related changes in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophrenia Research 1996; 22: 5–17
   PubMed Web of Science ®Google Scholar
• Deicken RF, Zhou L, Schuff N, Fein G, Weiner MW. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biological Psychiatry 1998; 43: 483–488
   PubMed Web of Science ®Google Scholar
• Fukuzako H, Takeuchi K, Hokazono Y, et al. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Research: Neuroimaging 1995; 61: 193–200
   Web of Science ®Google Scholar
• Renshaw PF, Yurgelan‐Todd DA, Tohen M, Ed M, Gruber SA, Cohen BM. Temporal lobe proton magnetic resonance spectroscopy of patients with first‐episode psychosis. American Journal of Psychiatry 1995; 152: 444–446
   PubMed Web of Science ®Google Scholar
• Yurgelun‐Todd DA, Renshaw PF, Gruber SA, Ed M, Waternaux C, Cohen BM. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophrenia Research 1996; 19: 55–59
   PubMed Web of Science ®Google Scholar
• Callicott JH, Egan MF, Bertolino A, et al. Hippocampal N‐acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biological Psychiatry 1998; 44: 941–950
   PubMed Web of Science ®Google Scholar
• Benes FM, Turtle M, Khan Y, Farol P. Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Archives of General Psychiatry 1994; 51: 477–484
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Nakano T, Takano T, et al. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biological Psychiatry 1996; 40: 14–18
   PubMed Web of Science ®Google Scholar
• Shiori T, Hamakawa H, Kato T, et al. Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: a preliminary report. Schizophrenia Research 1996; 22: 19–26
   PubMed Web of Science ®Google Scholar
• Sharma R, Venkatasubramanian PN, Barany M, Davis JM. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophrenia Research 1992; 8: 43–49
   PubMed Web of Science ®Google Scholar
• Omori M, Pearce J, Komoroski RA, et al. In vitro 1H‐magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biological Psychiatry 1997; 42: 359–366
   PubMed Web of Science ®Google Scholar
• Durst P, Schuff N, Crocq M‐A, Mokrani M‐C, Macher J‐P. Noninvasive in vivo detection of a fluorinated neuroleptic in the human brain by 19F‐nuclear magnetic resonance‐spectroscopy. Psychiatry Research. Neuroimaging 1990; 35: 107–114
   Web of Science ®Google Scholar
• Bartels M, Gunther U, Albert K, Mann K, Schuff N, Stuckstedte H. 19F nuclear magnetic resonance spectroscopy of neuroleptics: the first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain. Biological Psychiatry 1991; 30: 656–662
   PubMed Web of Science ®Google Scholar
• Karson CN, Newton JE, Mohanakrishnan P, Sprigg J, Komoroski RA. Fluoxetine and trifluoperazine in the human brain: a 19F nuclear magnetic resonance spectroscopy study. Psychiatry Research 1992; 45: 95–104
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Montrose DM, Pierri JN, et al. Magnetic resonance imaging and spectroscopy in offspring at risk for schizophrenia: preliminary studies. Progress in Neuro‐psychopharmacology and Biological Psychiatry 1997; 21: 1285–1295
   PubMed Web of Science ®Google Scholar
• Cecil KM, Lenkinski RE, Gur RE, Gur RC. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naïve patients with schizophrenia. Neuropsychopharmacology 1999; 20: 131–140
   PubMed Web of Science ®Google Scholar
• Sullivan ML. Integrating qualitative and quantitative methods in the study of developmental psychopathology in context. Development and Psychopathology 1998; 10: 377–393
   PubMed Web of Science ®Google Scholar